XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
出版年份 2021 全文链接
标题
XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
作者
关键词
Neuroblastoma, Exportin-1, Selinexor, Bortezomib, IkB, NF-kB
出版物
Translational Oncology
Volume 14, Issue 8, Pages 101114
出版商
Elsevier BV
发表日期
2021-05-09
DOI
10.1016/j.tranon.2021.101114
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma
- (2020) Balakrishna Koneru et al. CANCER RESEARCH
- Selinexor: First Global Approval
- (2019) Yahiya Y. Syed DRUGS
- Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
- (2019) Rachel Sexton et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-kB pathway in preclinical models of pediatric high-grade glioma
- (2019) John A. DeSisto et al. MOLECULAR CANCER THERAPEUTICS
- Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)
- (2019) Sharon Ben-Barouch et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
- (2018) Ujjawal H. Gandhi et al. Clinical Lymphoma Myeloma & Leukemia
- Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
- (2018) Vinod Vijay Subhash et al. Scientific Reports
- Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
- (2018) Nizar J. Bahlis et al. BLOOD
- Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma
- (2017) Rajen Mody et al. PEDIATRIC BLOOD & CANCER
- Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
- (2017) Barbara Muz et al. Translational Oncology
- Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
- (2016) Ying Chen et al. CLINICAL CANCER RESEARCH
- First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
- (2016) Albiruni R. Abdul Razak et al. JOURNAL OF CLINICAL ONCOLOGY
- XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
- (2016) Joel G. Turner et al. Oncotarget
- Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
- (2016) Robert Nakayama et al. Oncotarget
- Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations
- (2015) Kristopher R. Bosse et al. CANCER
- Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy
- (2015) Weimin Gao et al. Journal of Thoracic Oncology
- Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program
- (2015) Edward F. Attiyeh et al. PEDIATRIC BLOOD & CANCER
- Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein
- (2015) Jo Ishizawa et al. PHARMACOLOGY & THERAPEUTICS
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- NF-κB Signaling Pathway Confers Neuroblastoma Cells Migration and Invasion Ability via the Regulation of CXCR4
- (2014) Kun Yang MEDICAL SCIENCE MONITOR
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276
- (2013) J Schmidt et al. LEUKEMIA
- CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas
- (2013) Fang Zhou et al. MEDICAL ONCOLOGY
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy
- (2013) P. Godwin et al. Frontiers in Oncology
- Normalization and missing value imputation for label-free LC-MS analysis
- (2012) Yuliya V Karpievitch et al. BMC BIOINFORMATICS
- Bortezomib: Understanding the Mechanism of Action
- (2011) B. Piperdi et al. MOLECULAR CANCER THERAPEUTICS
- Genome-Wide siRNA Screen for Modulators of Cell Death Induced by Proteasome Inhibitor Bortezomib
- (2010) Siquan Chen et al. CANCER RESEARCH
- Universal sample preparation method for proteome analysis
- (2009) Jacek R Wiśniewski et al. NATURE METHODS
- EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS
- (2009) Aiguo Shen et al. NEUROSURGERY
- DAnTE: a statistical tool for quantitative analysis of -omics data
- (2008) A. D. Polpitiya et al. BIOINFORMATICS
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer
- (2008) Aurelia Noske et al. CANCER
- Cyclin D1 and CDK4 Activity Contribute to the Undifferentiated Phenotype in Neuroblastoma
- (2008) J. J. Molenaar et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search